Divi's Laboratories Limited

Equities

DIVISLAB

INE361B01024

Pharmaceuticals

Delayed NSE India S.E. 08:01:59 2024-03-28 am EDT 5-day change 1st Jan Change
3,445 INR +2.30% Intraday chart for Divi's Laboratories Limited -0.58% -11.75%

This article is reserved for members

Already a member?

Log In

Not a member ?

Free registration
Indian Equities Close Lower on Monday, Draagged by Major Banking, Financial Companies MT
INDIA STOCKS-Energy shares drag India's blue-chip stocks; small, mid-caps slide RE
Transcript : Divi's Laboratories Limited, Q3 2024 Earnings Call, Feb 10, 2024
Divi's Laboratories Limited Reports Earnings Results for the Third Quarter and Nine Months Ended December 31, 2023 CI
Indian Equities Break Five-Day Winning Streak on Tuesday, Dragged by Realty, IT Stocks MT
INDIA STOCKS-Indian shares decline amid selling pressure in financials, IT RE
Indian Equities End Higher for Third Straight Day on Tuesday, Lifted by US Inflation Drop MT
Indian Equities End Higher Midweek, Led by Gains in Bank, Auto and IT Stocks MT
Selling in IT Drags Indian Equities to Close Lower on Friday MT
INDIA STOCKS-Indian shares lacklustre as IT stocks snap rally RE
Profit Booking Amid Weak Global Cues Drags Indian Equities to End Flat on Tuesday MT
Jefferies Downgrades Divi’s Laboratories to Hold From Buy, Adjusts Price Target to INR3,510 From INR4,300 MT
Divi's Laboratories' Consolidated Profit Slides in Fiscal Q2; EPS, Revenue Miss Estimates MT
Indian Equities End Higher for Third Time on Monday on Expected Imminent End to Rate Hikes MT
Transcript : Divi's Laboratories Limited, Q2 2024 Earnings Call, Nov 06, 2023
Divi's Laboratories Limited Reports Earnings Results for the Second Quarter and Six Months Ended September 30, 2023 CI
Potential US Interest Rate Hikes, Israel-Hamas War Drag Indian Equities to End Lower as Week Ends MT
Indian Equities End Lower for Third Straight Day on Monday Amid Escalating Israel-Hamas War MT
Indian Equities Continue Rally Despite Gloomy Global Cues, Aided By Strong Outlook for Domestic Economy MT
Divi's Laboratories Limited Informs Resignations of Directors CI
Divi's Laboratories Limited Declares Dividend for the Financial Year Ended March 31, 2023 CI
Indian Equities Close Lower After Profit Booking Erases Gains MT
Indian Equities Close Higher, Led by Financial Stocks MT
Jefferies Adjusts Divi’s Laboratories’ Price Target to INR4,300 From INR3,610, Keeps at Buy MT
Divi's Laboratories' Consolidated Profit Slumps in Fiscal Q1 MT
Chart Divi's Laboratories Limited
More charts
Divi's Laboratories Limited is specialized in the development and manufacture of active pharmaceutical ingredients, intermediates and nutraceutical ingredients. Net sales by source of revenue break down into product sales (97.9%) and service sales (2.1%). At the end of March 2020, the group has 2 production sites located in India.
Related indices
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
B
More Ratings
Sell
Consensus
Buy
Mean consensus
UNDERPERFORM
Number of Analysts
23
Last Close Price
3,445 INR
Average target price
3,415 INR
Spread / Average Target
-0.89%
Consensus
  1. Stock
  2. Equities
  3. Stock Divi's Laboratories Limited - NSE India S.E.
  4. News Divi's Laboratories Limited
  5. Divi Laboratories : MSD Allows Divi's Laboratories to Manufacture, Supply Molnupiravir API